Now, a phase 3 clinical trial published in The Lancet gives new hope to those affected by the rare condition. The therapy, called deramiocel, is grown from heart cells that were donated for transplant but could not be used. Across all participants, the therapy made no clear difference to how well the heart pumped blood. Among the 64 participants who already had heart muscle disease and had suitable heart scans, heart function was better preserved with deramiocel than with placebo. Read the study: Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial – The Lancet.